Blood pressure reduction and cardiovascular prevention: An update including the 2003-2004 secondary prevention trials

Hypertension Research

Volumn 28, Issue 5, 2005, Pages 385-407

  Staessen, Jan A ^a,c   Li, Yan ^b   Thijs, Lutgarde ^a   Wang, Ji Guang ^b  

^a KU LEUVEN DEPARTMENT OF REHABILITATION SCIENCES   (Belgium)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Blood pressure; Clinical trial; Heart failure; Myocardial infarction; Stroke

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; ATENOLOL; BENDROFLUMETHIAZIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CHLORTALIDONE; DIHYDROPYRIDINE DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOXAZOSIN; ENALAPRIL; IRBESARTAN; LACIDIPINE; LISINOPRIL; NEW DRUG; NIFEDIPINE; NISOLDIPINE; PERINDOPRIL; PLACEBO; RAMIPRIL; TRANDOLAPRIL; UNINDEXED DRUG; VALSARTAN; VERAPAMIL;

BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COUGHING; DRUG EFFICACY; DRUG SAFETY; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERTENSION; META ANALYSIS; REVIEW; SECONDARY PREVENTION; STROKE; SYSTEMATIC REVIEW; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CEREBROVASCULAR ACCIDENT; HUMANS; HYPERTENSION;

EID: 22544437310     PISSN: 09169636     EISSN: None     Source Type: Journal    
DOI: 10.1291/hypres.28.385     Document Type: Review

References (155)

1. Prospective Studies Collaboration: Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. [i#Lancet#1i] 2002; [b#360#1b]: 1903-1913.
2. Asia Pacific Cohort Studies Collaboration: Blood pressure and cardiovascular disease in the Asia Pacific region. [i#J Hypertens#1i] 2003; [b#21#1b]: 707-716.
3. European Society of Hypertension/European Society of Cardiology Guidelines Committee: 2003 European Society of Hypertension/European Society of Cardiology guidelines for the management of arterial hypertension. [i#J Hypertens#1i] 2003; [b#21#1b]: 1011-1053.
4. Chobanian AV, Bakris GL, Black BK, [i#et al#1i]: The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The JNC 7 Report. [i#JAMA#1i] 2003; [b#289#1b]: 2560-2572.
5. Staessen JA, Wang JG, Thijs L: Cardiovascular prevention and blood pressure reduction: a meta-analysis. [i#Lancet#1i] 2001; [b#358#1b]: 1305-1315 (erratum published in [i#Lancet#1i] 2002; [b#359#1b]: 360).
6. Staessen JA, Wang JG, Thijs L: Calcium-channel blockade and cardiovascular prognosis: recent evidence from clinical outcome trials. [i#Am J Hypertens#1i] 2002; [b#15#1b]: 85S-93S.
7. Staessen JA, Wang JG, Thijs L: Cardiovascular prevention and blood pressure reduction: a quantitative overview updated until March 2003. [i#J Hypertens#1i] 2003; [b#21#1b]: 1055-1076.
8. Borhani NO, Mercuri M, Borhani PA, [i#et al#1i]: Final outcome results of the multicenter isradipine diuretic atherosclerosis study (MIDAS). A randomized controlled trial. [i#JAMA#1i] 1996; [b#276#1b]: 785-791.
9. Hansson L, Lindholm LH, Niskanen L, [i#et al#1i]: Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. [i#Lancet#1i] 1999; [b#353#1b]: 611-616.
10. National Intervention Cooperative Study in Elderly Hypertensives Study Group: Randomized double-blind comparison of a calcium antagonist and a diuretic in elderly hypertensives. [i#Hypertension#1i] 1999; [b#34#1b]: 1129-1133.
11. Hansson L, Lindholm LH, Ekbom T, [i#et al#1i]: Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity in the Swedish Trial in Old Patients with Hypertension-2 study. [i#Lancet#1i] 1999; [b#354#1b]: 1751-1756.
12. Brown MJ, Palmer CR, Castaigne A, [i#et al#1i]: Morbidity and mortality in patients randomised to double-blind treatment with long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS Study: Intervention as a Goal in Hypertensive Treatment (INSIGHT). [i#Lancet#1i] 2000; [b#356#1b]: 366-372.
13. Hansson L, Hedner T, Lund-Johansen P, [i#et al#1i]: Randomised trial of effects of calcium antagonists compared with diuretics and β-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. [i#Lancet#1i] 2000; [b#356#1b]: 359-365.
14. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group: Major cardiovascular events in hypertensive patients randomized to doxazosin [i#vs#1i] chlorthalidone. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). [i#JAMA#1i] 2000; [b#283#1b]: 1967-1975.
15. Agabiti Rosei E, Dal Palú C, Leonetti G, [i#et al#1i]: Clinical results of the Verapamil in Hypertension and Atherosclerosis Study. [i#J Hypertens#1i] 1997; [b#15#1b]: 1337-1344.
16. UK Prospective Diabetes Study Group: Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. [i#BMJ#1i] 2000; [b#317#1b]: 713-720.
17. Lindholm LH, Ibsen H, Dahlöf B, [i#et al#1i]: Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. [i#Lancet#1i] 2002; [b#359#1b]: 1004-1010.
18. Dahlöf B, Devereux RB, Kjeldsen SE, [i#et al#1i]: Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. [i#Lancet#1i] 2002; [b#359#1b]: 995-1003.
19. Black HR, Elliott WJ, Grambsch P, [i#et al#1i]: Principal results of the Controlled ONset Verapamil INvestigation of Cardiovascular Endpoints (CONVINCE) Trial. [i#JAMA#1i] 2003; [b#289#1b]: 2073-2082.
20. Zanchetti A, Bond G, Hennig M, [i#et al#1i]: Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis. Principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial. [i#Circulation#1i] 2002; [b#106#1b]: 2422-2427.
21. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group: Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker [i#vs.#1i] diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). [i#JAMA#1i] 2002; [b#288#1b]: 2981-2997.
22. Zanchetti A, Bond MG, Hennig M, [i#et al#1i]: Risk factors associated with alterations in carotid intima-media thickness in hypertension: baseline data from the European Lacidipine Study on Atherosclerosis. [i#J Hypertens#1i] 1998; [b#16#1b]: 949-961.
23. Wing LMH, Reid CM, Ryan P, [i#et al#1i]: A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. [i#N Engl J Med#1i] 2003; [b#348#1b]: 583-592.
24. Lithell H, Hansson L, Skoog I, [i#et al#1i]: The study on cognition and prognosis in the elderly (SCOPE). Principal results of a randomised double-blind intervention trial. [i#J Hypertens#1i] 2003; [b#21#1b]: 875-886.
25. Bulpitt CJ, Beckett NS, Cooke J, [i#et al#1i]: Results of the pilot study for the Hypertension in the Very Elderly Trial. [i#J Hypertens#1i] 2003; [b#21#1b]: 2409-2417.
26. Zanchetti A, Agabiti Rosei E, Dal Palú C, [i#et al#1i]: The Verapamil in Hypertension and Atherosclerosis Study (VHAS): results of long-term randomized treatment with either verapamil or chlorthalidone on carotid intima-media thickness. [i#J Hypertens#1i] 1998; [b#16#1b]: 1667-1676.
27. Helgeland A: Treatment of mild hypertension: a five year controlled drug trial. [i#Am J Med#1i] 1980; [b#69#1b]: 725-732.
28. Black HR, Elliott WJ, Neaton JD, [i#et al#1i]: Baseline characteristics and early blood pressure control in the CONVINCE trial. [i#Hypertension#1i] 2001; [b#37#1b]: 12-18.
29. Pepine CJ, Handberg EM, Cooper-DeHoff RM, [i#et al#1i]: A calcium antagonist [i#vs#1i] a non-calcium antagonist hypertension treatment strategy for patients with coronary heart disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. [i#JAMA#1i] 2003; [b#290#1b]: 2805-2816.
30. Malacco E, Mancia G, Rappelli A, [i#et al#1i]: Treatment of isolated systolic hypertension: the SHELL study results. [i#Blood Press#1i] 2003; [b#12#1b]: 160-167.
31. Agodoa LY, Appel L, Bakris GL, [i#et al#1i]: Effect of ramipril [i#vs#1i] amlodipine on renal outcomes in hypertensive nephrosclerosis. [i#JAMA#1i] 2001; [b#285#1b]: 2719-2728.
32. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group: Diuretic [i#versus#1i] α-blocker as first step antihypertensive therapy. Final results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). [i#Hypertension#1i] 2003; [b#42#1b]: 239-246.
33. Lewis EJ, Hunsicker LG, Clarke WR, [i#et al#1i]: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. [i#N Engl J Med#1i] 2001; [b#345#1b]: 851-860.
34. Rodby RA, Rohde RD, Clarke WR, [i#et al#1i]: The Irbesartan Type II Diabetic Nephropathy Trial: study design and baseline patient characteristics. [i#Nephrol Dial Transplant#1i] 2000; [b#15#1b]: 487-497.
35. Berl T, Hunsicker LG, Lewis JB, [i#et al#1i]: Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy. [i#Arch Intern Med#1i] 2003; [b#138#1b]: 542-549.
36. Julius S, Kjeldsen SE, Brunner H, [i#et al#1i]: VALUE Trial: long-term blood pressure trends in 13,449 patients with hypertension and high cardiovascular risk. [i#Am J Hypertens#1i] 2003; [b#16#1b]: 544-548.
37. Mann J, Julius S, for the VALUE Trial Group: The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) Trial of cardiovascular events in hypertension. Rationale and design. [i#Blood Press#1i] 1998; [b#7#1b]: 176-183.
38. Kjeldsen SE, Julius S, Brunner H, [i#et al#1i]: Characteristics of 15 314 hypertensive patients at high coronary risk. The VALUE Trial. [i#Blood Press#1i] 2001; [b#10#1b]: 83-91.
39. Julius S, Kjeldsen SE, Weber M, [i#et al#1i]: Outcomes in hypertensive patients at high cardiovascular risk treated with valsartan- or amlodipine-based regimens: VALUE, a randomised trial. [i#Lancet#1i] 2004; [b#363#1b]: 2022-2031.
40. Weber MA, Julius S, Kjeldsen SE, [i#et al#1i]: Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. [i#Lancet#1i] 2004; [b#363#1b]: 2049-2051.
41. Nissen SE, Tuzcu EM, Libby P, [i#et al#1i]: Effect of antihypertensive agents on cardiovascular events in patients with coronary heart disease and normal blood pressure. The CAMELOT study: a randomized controlled trial. [i#JAMA#1i] 2004; [b#292#1b]: 2217-2226.
42. Byington RB, Miller ME, Herrington D, [i#et al#1i]: Rationale, design, and baseline characteristics of the Prospective Randomized Evaluation of the Vascular Effects of Norvasc Trial (PREVENT). [i#Am J Cardiol#1i] 1997; [b#80#1b]: 1087-1090.
43. Pitt B, Byington RP, Furberg CD, [i#et al#1i]: Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. [i#Circulation#1i] 2000; [b#102#1b]: 1503-1510.
44. Poole-Wilson PA, Lubsen J, Kirwan BA, [i#et al#1i]: Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomised controlled trial. [i#Lancet#1i] 2004; [b#364#1b]: 849-857.
45. Lubsen J, Poole-Wilson PA, Pocock SJ, [i#et al#1i]: Design and current status of ACTION: A Coronary disease Trial Investigating Outcome with Nifedipine GITS. [i#Eur Heart J#1i] 1998; [b#19#1b] (Suppl I): I20-I32.
46. Dens JA, Desmet WJ, Coussement P, [i#et al#1i]: Usefulness of nisoldipine for prevention of restenosis after percutaneous transluminal coronary angioplasty (results of the NICOLE study). NIsoldipine in COronary artery disease in LEuven. [i#Am J Cardiol#1i] 2001; [b#87#1b]: 28-33.
47. Dens JA, Desmet WJ, Coussement P, [i#et al#1i]: Long term effects of nisoldipine on the progression of coronary atherosclerosis and the occurrence of clinical events: the NICOLE study. [i#Heart#1i] 2003; [b#89#1b]: 887-892.
48. Teo KK, Burton JR, Buller CE, [i#et al#1i]: Long-term effects of cholesterol lowering and angiotensin-converting enzyme inhibition on coronary atherosclerosis. The Simvastatin/Enalapril Coronary Atherosclerosis Trial (SCAT). [i#Circulation#1i] 2000; [b#102#1b]: 1748-1754.
49. The European Trial on Reduction of Cardiac Events with Perindopril in Stable Coronary Artery Disease Investigators: Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary heart disease: randomised double-blind, placebo-controlled, multicentre trial (the EUROPA study). [i#Lancet#1i] 2003; [b#362#1b]: 782-788.
50. Neal B, MacMahon S, on behalf of the PROGRESS Management Committee: The PROGRESS study: rationale and design. [i#J Hypertens#1i] 1995; [b#13#1b]: 1869-1873.
51. PROGRESS Collaborative Group: Randomised trial of a perindopril-based blood pressure lowering regimen among 6105 individuals with prior stroke or transient ischaemic attack. [i#Lancet#1i] 2001; [b#358#1b]: 1033-1041.
52. Lièvre M, Marre M, Chatellier G, [i#et al#1i]: The non-insulin dependent diabetes, hypertension, microalbuminuria or proteinuria, cardiovascular events, and ramipril (DIABHY-CAR) study: design, organization, and patient recruitment. [i#Control Clin Trials#1i] 2000; [b#21#1b]: 383-396.
53. Marre M, Lièvre M, Vasmant D, [i#et al#1i]: Determinants of elevated urinary albumin in the 4,937 type 2 diabetic subjects recruited for the DIABHYCAR study in Western Europe and Northern Africa. [i#Diabet Care#1i] 2000; [b#23#1b] (Suppl 2): B40-B48.
54. Marre M, Lievre M, Chatellier G, [i#et al#1i]: Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomised, double blind, placebo controlled trial (the DIABHYCAR study). [i#BMJ#1i] 2004; [b#328#1b]: 495-501 (erratum published in [i#BMJ#1i] 2004; [b#328#1b]: 686).
55. The Heart Outcomes Prevention Evaluation Study Investigators: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. [i#N Engl J Med#1i] 2000; [b#342#1b]: 145-153.
56. Heart Outcomes Prevention Evaluation Study Investigators: Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. [i#Lancet#1i] 2000; [b#355#1b]: 253-259.
57. MacMahon S, Sharpe N, Gamble G, [i#et al#1i]: Randomized, placebo-controlled trial of the angiotensin-converting enzyme inhibitor, ramipril, in patients with coronary or other occlusive arterial disease. [i#J Am Coll Cardiol#1i] 2000; [b#36#1b]: 438-443.
58. The PEACE Trial Investigators: Angiotensin-converting-enzyme inhibition in stable coronary heart artery disease. [i#N Engl J Med#1i] 2004; [b#351#1b]: 2058-2068.
59. PROGRESS Collaborative Group: Effects of perindopril-based blood pressure lowering regimen on cardiac outcomes among patients with cerebrovascular disease. [i#Eur Heart J#1i] 2003; [b#24#1b]: 475-484.
60. Wright JT Jr, Bakris G, Greene T, [i#et al#1i]: Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease. Results from the AASK trial. [i#JAMA#1i] 2002; [b#288#1b]: 2421-2431.
61. Estacio RO, Jeffers BW, Hiatt WR, Biggerstaff SL, Gifford N, Schrier RW: The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. [i#N Engl J Med#1i] 1998; [b#338#1b]: 645-652.
62. Estacio RO, Savage S, Nagel NJ, Schrier RW: Baseline characteristics of participants in the Appropriate Blood Pressure Control in Diabetes trial. [i#Control Clin Trials#1i] 1996; [b#17#1b]: 242-257.
63. Estacio RO, Jeffers BW, Gifford N, Schrier RW: Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. [i#Diabet Care#1i] 2000; [b#23#1b] (Suppl 2): B54-B64.
64. Schrier RW, Estacio RO: Additional follow-up from the ABCD trial in patients with type 2 diabetes and hypertension. [i#N Engl J Med#1i] 2000; [b#343#1b]: 1969.
65. Schrier RW, Estacio RO, Esler A, Mehler P: Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. [i#Kidney Int#1i] 2002; [b#61#1b]: 1086-1097.
66. Ruggenenti P, Remuzzi G, on behalf of the Bergamo Diabetic Nephrologic Study Group: Primary prevention of renal failure in diabetic patients: the Bergamo Nephrologic Diabetes Complications Trial. [i#J Hypertens#1i] 1998; [b#16#1b]: S95-S97.
67. Ruggenenti P, Fassi A, Parvanova Ilieva A, [i#et al#1i]: Preventing microalbuminuria in type 2 diabetes. [i#N Engl J Med#1i] 2004; [b#351#1b]: 1941-1951.
68. Mogensen CE, Neldam S, Tikkanen I, [i#et al#1i]: Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria study (CALM) study. [i#BMJ#1i] 2000; [b#321#1b]: 1440-1444.
69. Parving HH, Lehnert H, Bröchner-Mortensen J, [i#et al#1i]: The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. [i#N Engl J Med#1i] 2001; [b#345#1b]: 870-878.
70. Levey AS, Greene T, Schluchter MD, [i#et al#1i]: Glomerular filtration rate measurements in clinical trials. [i#J Am Soc Nephrol#1i] 1993; [b#4#1b]: 1159-1171.
71. Brenner BM, Cooper ME, de Zeeuw D, [i#et al#1i]: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. [i#N Engl J Med#1i] 2001; [b#345#1b]: 861-869.
72. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD, for the Collaborative Study Group: The effect of angiotensin-converting enzyme inhibition on diabetic nephropathy. [i#N Engl J Med#1i] 1993; [b#329#1b]: 1456-1462.
73. Hansson L, Hedner T, Lindholm L, [i#et al#1i]: The Captopril Prevention Project (CAPPP) in hypertension - baseline data and current status. [i#Blood Press#1i] 1997; [b#6#1b]: 365-367.
74. Mancia G, Brown M, Castaigne A, [i#et al#1i]: Outcomes with nifedipine GITS or co-amilozide in hypertensive diabetics and nondiabetics in Intervention as a Goal in Hypertension (INSIGHT). [i#Hypertension#1i] 2003; [b#41#1b]: 431-436.
75. UK Prospective Diabetes Study Group: Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. [i#BMJ#1i] 1998; [b#317#1b]: 703-713.
76. Hansson L, Zanchetti A, Carruthers SG, [i#et al#1i]: Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. [i#Lancet#1i] 1998; [b#351#1b]: 1755-1762.
77. SHEP Cooperative Research Group: Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). [i#JAMA#1i] 1991; [b#265#1b]: 3255-3264.
78. Curb JD, Pressel SL, Cutler JA, [i#et al#1i]: Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. [i#JAMA#1i] 1996; [b#276#1b]: 1886-1892.
79. Liu L, Wang JG, Gong L, Liu G, Staessen JA, for the Systolic Hypertension in China (Syst-China) Collaborative Group: Comparison of active treatment and placebo in older patients with isolated systolic hypertension. [i#J Hypertens#1i] 1998; [b#16#1b]: 1823-1829.
80. Wang JG, Staessen JA, Gong L, Liu L, for the Systolic Hypertension in China (Syst-China) Collaborative Group: Chinese trial on isolated systolic hypertension in the elderly. [i#Arch Intern Med#1i] 2000; [b#160#1b]: 211-220.
81. Staessen JA, Fagard R, Thijs L, [i#et al#1i]: Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. [i#Lancet#1i] 1997; [b#350#1b]: 757-764 (erratum published in [i#Lancet#1i] 1997; [b#350#1b]: 1636).
82. Tuomilehto J, Rastenyte D, Birkenhäger WH, [i#et al#1i]: Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. [i#N Engl J Med#1i] 1999; [b#340#1b]: 677-684.
83. Staessen JA, Thijs L, Birkenhäger WH, Bulpitt CJ, Fagard R, on behalf of the Syst-Eur Investigators: Update on the Systolic Hypertension in Europe (Syst-Eur) Trial. [i#Hypertension#1i] 1999; [b#33#1b]: 1476-1477.
84. PATS Collaborative Group: Post-stroke antihypertensive treatment study. A preliminary result. [i#Chin Med J#1i] 1995; [b#108#1b]: 710-717.
85. PROGRESS Management Committee: PROGRESS - Perindopril Protection against Recurrent Stroke Study: characteristics of the study population at baseline. [i#J Hypertens#1i] 1999; [b#17#1b]: 1647-1655.
86. Coope J, Warrender TS: Randomised trial of treatment of hypertension in elderly patients in primary care. [i#BMJ#1i] 1986; [b#293#1b]: 1145-1151.
87. Management Committee: The Australian Therapeutic Trial in Mild Hypertension. [i#Lancet#1i] 1980; [b#i#1b]: 1261-1267.
88. Amery A, Birkenhäger W, Brixko P, [i#et al#1i]: Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial. [i#Lancet#1i] 1985; [b#i#1b]: 1349-1354.
89. European Working Party on High Blood Pressure in the Elderly (EWPHE): An international trial of antihypertensive therapy in elderly patients. Objectives, protocol and organization. [i#Arch Intern Pharmacodyn Ther#1i] 1985; [b#275#1b]: 300-334.
90. Hypertension-Stroke Cooperative Study Group: Effect of antihypertensive treatment on stroke recurrence. [i#JAMA#1i] 1974; [b#229#1b]: 409-418.
91. Medical Research Council Working Party: MRC trial of treatment of mild hypertension: principal results. [i#BMJ#1i] 1985; [b#291#1b]: 97-104.
92. MRC Working Party: Medical Research Council trial of treatment of hypertension in older adults: principal results. [i#BMJ#1i] 1992; [b#304#1b]: 405-412.
93. Dahlöf B, Lindholm LH, Hansson L, Scherstén B, Ekbom T, Wester PO: Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). [i#Lancet#1i] 1991; [b#338#1b]: 1281-1285.
94. Gong L, Zhang W, Zhu Y, [i#et al#1i]: Shanghai trial of nifedipine in the elderly (STONE). [i#J Hypertens#1i] 1996; [b#14#1b]: 1237-1245.
95. US Public Health Service Hospitals Cooperative Study Group (McFate Smith WM): Treatment of mild hypertension: results of a ten-year intervention trial. [i#Circ Res#1i] 1977; [b#40#1b]: I-98-I-105.
96. Veterans Administration Cooperative Study Group on Antihypertensive Agents: Effect of treatment on morbidity in hypertension: results in patients with diastolic blood pressure averaging 115-129 mmHg. [i#JAMA#1i] 1967; [b#202#1b]: 116-122.
97. Kuramoto K, Matsushita S, Kuwajima I, Murakami M: Prospective study on the treatment of mild hypertension in the aged. [i#Jpn Heart J#1i] 1981; [b#22#1b]: 75-85.
98. Wolff FW, Lindeman RD: Effects of treatment in hypertension: results of a controlled study. [i#J Chron Dis#1i] 1966; [b#19#1b]: 227-240.
99. Carter AB: Hypotensive therapy in stroke survivors. [i#Lancet#1i] 1970; [b#1#1b]: 485-489.
100. Veterans Administration-NHLBI Study Group for Cooperative Studies on Antihypertensive Therapy: Mild Hypertension (Perry HM Jr): Treatment of mild hypertension: preliminary results of a two-year feasibility trial. [i#Circ Res#1i] 1977; [b#40#1b]: I-180-I-187.
101. Veterans Administration Cooperative Study Group on Antihypertensive Agents: Effects of treatment on morbidity in hypertension II. Results in patients with diastolic blood pressure averaging 90 through 114 mmHg. [i#JAMA#1i] 1970; [b#213#1b]: 1143-1152.
102. Hypertension Detection and Follow-Up Program Cooperative Group: Five-year findings of the Hypertension Detection and Follow-Up Program. I. Reduction in mortality of persons with high blood pressure, including mild hypertension. [i#JAMA#1i] 1979; [b#242#1b]: 2562-2571.
103. Hypertension Detection and Follow-Up Program Cooperative Group: Five-year findings of the Hypertension Detection and Follow-Up Program. III. Reduction in stroke incidence among persons with high blood pressure. [i#JAMA#1i] 1982; [b#247#1b]: 633-638.
104. Casiglia E, Spolaore P, Mazza A, [i#et al#1i]: Effect of 2 different therapeutic approaches on total and cardiovascular mortality in a cardiovascular study in the elderly. [i#Jpn Heart J#1i] 1994; [b#35#1b]: 589-600.
105. Staessen JA, Wang JG: Blood-pressure lowering for the secondary prevention of stroke. [i#Lancet#1i] 2001; [b#358#1b]: 1026-1027.
106. Dahlöf B, Devereux R, de Faire U, [i#et al#1i]: The Losartan Intervention For Endpoint reduction (LIFE) in hypertension study: rationale, design and methods. [i#Am J Hypertens#1i] 1997; [b#10#1b]: 705-713.
107. Lindholm LH, Ibsen H, Borch-Johnsen K, [i#et al#1i]: Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study. [i#J Hypertens#1i] 2002; [b#20#1b]: 1879-1886.
108. Hansson L, Lithell H, Skoog I, [i#et al#1i]: Study on COgnition and Prognosis in the Elderly (SCOPE). [i#Blood Press#1i] 1999; [b#8#1b]: 177-183.
109. Lithell H, Hansson L, Skoog I, [i#et al#1i]: The Study on COgnition and Prognosis in the Elderly (SCOPE): outcomes in patients not receiving add-on therapy after randomisation. [i#J Hypertens#1i] 2004; [b#22#1b]: 1605-1612.
110. Wright JT, Kusek JW, Toto RD, [i#et al#1i]: Design and baseline characteristics of participants in the African American Study of Kidney disease and hypertension (AASK) pilot study. [i#Control Clin Trials#1i] 1996; [b#16#1b]: 3S-16S.
111. World Health Organization-International Society of Hypertension Blood Pressure Lowering Treatment Trialists' Collaboration: Protocol for prospective collaborative overviews of major randomized trials of blood-pressure-lowering treatments. [i#J Hypertens#1i] 1998; [b#16#1b]: 127-137.
112. Blood Pressure Lowering Treatment Trialists' Collaboration: Effects of ACE inhibitors, calcium antagonists, and other blood pressure-lowering drugs: results of prospectively designed overviews of randomised trials. [i#Lancet#1i] 2000; [b#355#1b]: 1955-1964.
113. Blood Pressure Lowering Treatment Trialists' Collaboration: Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. [i#Lancet#1i] 2003; [b#362#1b]: 1527-1535.
114. Wright JT Jr, Agodoa L, Contreras G, [i#et al#1i]: Successful blood pressure control in the African American Study of Kidney Disease and Hypertension. [i#Arch Intern Med#1i] 2002; [b#162#1b]: 1636-1643.
115. Reugg UT, Wallnofer A, Weir S, Cauvin C: Receptor-operated calcium-permeable channels in vascular smooth muscle. [i#J Cardiovasc Pharmacol#1i] 1989; [b#14#1b] (Suppl 6): S49-S58.
116. Eriksson S, Olofsson BO, Wester PO, for the TEST Study Group: Atenolol in the secondary prevention of stroke. [i#Cerebrovasc Dis#1i] 1995; [b#5#1b]: 21-25.
117. Bronner LL, Kanter DS, Manson JE: Primary prevention of stroke. [i#N Engl J Med#1i] 1995; [b#333#1b]: 1392-1400.
118. Management Committee on behalf of the High Blood Pressure Research Council of Australia: Australian comparative outcome trial of angiotensin-converting enzyme inhibitor- and diuretic-based treatment of hypertension in the elderly (ANBP2): objectives and protocol. [i#Clin Exp Pharmacol Physiol#1i] 1997; [b#24#1b]: 188-192.
119. Yui Y, Sumiyoshi T, Kodama K, [i#et al#1i]: Comparison of nifedipine retard with angiotensin converting enzyme inhibitors in Japanese hypertensive patients with coronary heart disease: the Japan multicenter investigation for cardiovascular diseases-B (JMIC-B) randomized trial. [i#Hypertens Res#1i] 2004; [b#27#1b]: 181-191.
120. Sever PS, Dahlöf B, Poulter NR, [i#et al#1i]: Rationale, design, methods and baseline demography of participants of the Anglo-Scandinavian Cardiac Outcomes Trial. [i#J Hypertens#1i] 2001; [b#19#1b]: 1139-1147.
121. Sever PS, Dahlöf B, Poulter NR, [i#et al#1i]: Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOTT-LLA): a multicentre randomised controlled trial. [i#Lancet#1i] 2003; [b#361#1b]: 1149-1158.
122. Rousseau MF, Melin J, Benedict CR, [i#et al#1i]: Effects of nisoldipine therapy on myocardial perfusion and neuro-humoral status in patients with severe ischaemic left ventricular dysfunction. [i#Eur Heart J#1i] 1994; [b#15#1b]: 957-964.
123. Thrackray S, Witte K, Clark AL, Cleland JGF: Clinical trials update: OPTIME-CHF, PRAISE-2, ALLHAT. [i#Eur J Heart Failure#1i] 2000; [b#2#1b]: 209-212.
124. Packer M, O'Connor CM, Ghali JK, [i#et al#1i]: Effect of amlodipine on morbidity and mortality in severe chronic heart failure. [i#N Engl J Med#1i] 1996; [b#335#1b]: 1107-1114.
125. Figulla HR, Gietzen F, Zeymer U, [i#et al#1i]: Diltiazem improves cardiac function and exercise capacity in patients with idiopathic dilated cardiomyopathy. Results of the Diltiazem in Dilated Cardiomyopathy Trial. [i#Circulation#1i] 1996; [b#94#1b]: 346-352.
126. The Danish Study Group on Verapamil in Myocardial Infarction: Secondary prevention with verapamil after myocardial infarction. [i#Am J Cardiol#1i] 1990; [b#66#1b]: 33I-40I.
127. Cleland JGF, Swedberg K, Poole-Wilson PA: Successes and failures in current treatment of heart failure. [i#Lancet#1i] 1998; [b#652#1b] (Suppl 1): 9-28.
128. Yusuf S, Pfeffer MA, Swedberg K, [i#et al#1i]: Effects of candesartan in patients with chronic heart failure and preserved left-ventricular systolic function: the CHARM-Alternative trial. [i#Lancet#1i] 2003; [b#362#1b]: 777-781.
129. Granger CB, McMurray JJV, Yusuf S, [i#et al#1i]: Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. [i#Lancet#1i] 2003; [b#362#1b]: 772-776.
130. McMurray JJV, Östergren J, Swedberg K, [i#et al#1i]: Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. [i#Lancet#1i] 2003; [b#362#1b]: 767-771.
131. White HD: Should all patients with coronary heart disease receive angiotensin-converting-enzyme inhibitors? [i#Lancet#1i] 2003; [b#362#1b]: 755-757.
132. Pitt B, Poole-Wilson PA, Segal R, [i#et al#1i]: Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial. The Losartan Heart Failure Survival Study ELITE II. [i#Lancet#1i] 2000; [b#355#1b]: 1582-1587.
133. Dickstein K, Kjekshus J, the OPTIMAAL Steering Committee, for the OPTIMAAL Study Group: Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. [i#Lancet#1i] 2002; [b#360#1b]: 752-760.
134. Cohn JN, Tognoni G, for the Valsartan Heart Failure Trial Investigators: A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. [i#N Engl J Med#1i] 2001; [b#345#1b]: 1667-1675.
135. Pfeffer MA, McMurray JJV, Velazquez EJ, [i#et al#1i]: Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. [i#N Engl J Med#1i] 2003; [b#349#1b]: 1893-1906.
136. Packer M, Meller J, Gorlin R, Herman MV: Hemodynamic and clinical tachyphylaxis to prazosin-mediated after load reduction in severe chronic congestive heart failure. [i#Circulation#1i] 1979; [b#59#1b]: 531-539.
137. Lund-Johansen P: Intensive blood pressure lowering treatment: beneficial for all but the smoking hypertensives? [i#J Hypertens#1i] 2003; [b#21#1b]: 697-700.
138. Black HR, Elliott WJ, Neaton JD, [i#et al#1i]: Rationale and design for the controlled onset verapamil investigation of cardiovascular endpoints (CONVINCE) trial. [i#Control Clin Trials#1i] 1998; [b#19#1b]: 370-390.
139. Staessen J, Amery A, Fagard R: Editorial review. Isolated systolic hypertension in the elderly. [i#J Hypertens#1i] 1990; [b#8#1b]: 393-405.
140. Franklin SS, Larson MG, Khan SA, [i#et al#1i]: Does the relation of blood pressure to coronary heart disease change with aging? The Framingham Heart Study. [i#Circulation#1i] 2001; [b#103#1b]: 1245-1249.
141. ACE Inhibitor Myocardial Infarction Collaborative Group: Indications for ACE inhibitors in the early treatment of acute myocardial infarction. Systematic overview of individual patient data in randomized trials. [i#Circulation#1i] 1998; [b#97#1b]: 2202-2212.
142. Borghi C, Bacchelli S, Degli Esposti D, [i#et al#1i]: Effects of the administration of an angiotensin-converting enzyme inhibitor during the acute phase of myocardial infarction in patients with arterial hypertension. [i#Am J Hypertens#1i] 1999; [b#12#1b]: 665-672.
143. Materson BJ, Reda DJ, Cushman WC, [i#et al#1i]: Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. [i#N Engl J Med#1i] 1993; [b#328#1b]: 914-921.
144. Sareli P, Radevski IV, Valtchanova ZP, [i#et al#1i]: Efficacy of different drug classes used to initiate antihypertensive treatment in black subjects. Results of a randomized trial in Johannesburg, South Africa. [i#Arch Intern Med#1i] 2001; [b#161#1b]: 965-971.
145. Dickerson JEC, Hingorani AD, Ashby MJ, Palmer CR, Brown MJ: Optimisation of antihypertensive treatment by crossover rotation of four major drug classes. [i#Lancet#1i] 1999; [b#353#1b]: 2008-2013.
146. Brown MJ, Cruickshank JM, Dominiczak AF, [i#et al#1i]: Better blood pressure control: how to combine drugs? [i#J Hum Hypertens#1i] 2003; [b#17#1b]: 81-86.
147. Adrougué HJ, Wilson H, Boyd AE, Suki WN, Eknoyan G: Plasma acid-base patterns in diabetic ketoacidosis. [i#N Engl J Med#1i] 1982; [b#307#1b]: 1603-1610.
148. Staessen JA, Wang JG, Birkenhäger WH: Outcome beyond blood
149. 1-receptor mediated protective effect of angiotensin against acute ischaemic stroke in the gerbil. [i#J Renin Angiotensin Aldosterone Syst#1i] 2001; [b#2#1b]: 103-106.
150. Celentano A, Palmieri V, Di Palma Esposito N, [i#et al#1i]: Relations of pulse pressure and other components of blood pressure to preclinical echocardiographic abnormalities. [i#J Hypertens#1i] 2002; [b#20#1b]: 531-537.
151. de Simone G, Palmieri V, Bella JN, [i#et al#1i]: Association of left ventricular hypertrophy with metabolic risk factors: the HyperGEN study. [i#J Hypertens#1i] 2002; [b#20#1b]: 323-331.
152. Rothwell PM: External validity of randomised controlled trials: "to whom do the results of the trial apply?" [i#Lancet#1i] 2005; [b#365#1b]: 82-93.
153. Staessen JA, Thijs L, Fagard R, [i#et al#1i]: Effects of immediate [i#versus#1i] delayed antihypertensive therapy on outcome in the Systolic Hypertension in Europe Trial. [i#J Hypertens#1i] 2004; [b#22#1b]: 847-857.
154. Mancia G, Bombelli M, Lanzarotti A, [i#et al#1i]: Systolic [i#vs#1i] diastolic blood pressure control in the hypertensive patients of the PAMELA population. Pressioni Arteriose Monitorate E Loro Associazioni. [i#Arch Intern Med#1i] 2002; [b#162#1b]: 582-586.
155. Fagard RH, Van den Enden M: Treatment and blood pressure control in isolated systolic hypertension [i#vs#1i] diastolic hypertension in primary care. [i#J Hum Hypertens#1i] 2003; [b#17#1b]: 681-687.